Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
.
(
TST Recommends
Morning Bell With Jim Cramer: Spotting Market Rotation
TheStreet Founder Jim Cramer shares his thoughts about market rotations, the CPI, and Cathie Wood's ARK Innovation ETF.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.1%. By the end of trading, Vertex Pharmaceuticals fell 80 cents (-1.5%) to $53.87 on light volume. Throughout the day, 1.1 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 3.1 million shares. The stock ranged in price between $53.57-$54.66 after having opened the day at $54.51 as compared to the previous trading day's close of $54.67. Other companies within the Drugs industry that declined today were:
(
), down 7.1%,
(
), down 7%,
(
), down 5.9%, and
(
), down 5.7%.
- ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $10.72 billion and is part of the
sector. The company has a P/E ratio of 27.6, above the average drugs industry P/E ratio of 26.6 and above the S&P 500 P/E ratio of 17.7. Shares are up 64.5% year to date as of the close of trading on Wednesday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.
TheStreet Ratings rates Vertex Pharmaceuticals as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and increase in stock price during the past year. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good.
- You can view the full Vertex Ratings Report.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null
